Developmental origins of immunometabolic health-Immunometabolism-CSCIED科技核心评价数据库-手机版

Developmental origins of immunometabolic health

Developmental origins of immunometabolic health

ES评分 0 浏览量：128 下载量：0

DOI	10.1097/IN9.0000000000000075
刊名	Immunometabolism IJ
年，卷(期)	2026, 8(1)
作者	Alharithi, Yem J.; Smith, Gladys; Maloyan, Alina,
作者单位	Oregon Hlth Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA;
摘要	Obesity during pregnancy not only affects maternal health but also puts offspring at high risk of obesity and of metabolic and cardiovascular diseases later in life, often regardless of their own lifestyle choices. This process, known as developmental programming, is increasingly being recognized as a critical factor shaping long-term health outcomes. In addition, a growing body of research highlights the importance of immunometabolism, the metabolism of immune cells, in the pathogenesis of obesity, metabolic disorders, cardiovascular disease, and cancer. Although the effects of maternal obesity on offspring health have been well documented in both epidemiological studies and preclinical models, its influence on the developing immune system and immunometabolic pathways is only beginning to be revealed. In this review, we explore the metabolic and inflammatory dimensions of developmental programming and discuss how an adverse maternal environment may shape the offspring's immunometabolic landscape.
Abstract	Obesity during pregnancy not only affects maternal health but also puts offspring at high risk of obesity and of metabolic and cardiovascular diseases later in life, often regardless of their own lifestyle choices. This process, known as developmental programming, is increasingly being recognized as a critical factor shaping long-term health outcomes. In addition, a growing body of research highlights the importance of immunometabolism, the metabolism of immune cells, in the pathogenesis of obesity, metabolic disorders, cardiovascular disease, and cancer. Although the effects of maternal obesity on offspring health have been well documented in both epidemiological studies and preclinical models, its influence on the developing immune system and immunometabolic pathways is only beginning to be revealed. In this review, we explore the metabolic and inflammatory dimensions of developmental programming and discuss how an adverse maternal environment may shape the offspring's immunometabolic landscape.
关键词	pregnancy; immunometabolism; DOHAD; maternal obesity; developmental programming; inflammation; dipeptidyl peptidase 4
KeyWord	pregnancy; immunometabolism; DOHAD; maternal obesity; developmental programming; inflammation; dipeptidyl peptidase 4
基金项目
页码	-

参考文献
相关文献

[1]. Phelps NH, Singleton RK, Zhou B, et al. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027-50.

[2]. Roth GA, Mensah GA, Johnson CO, et al.; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021.

[3]. Kent L, McGirr M, Eastwood KA. Global trends in prevalence of maternal overweight and obesity: a systematic review and meta-analysis of routinely collected data retrospective cohorts. Int J Popul Data Sci. 2024;9(2):2401.

[4]. Ziauddeen N, Huang JY, Taylor E, et al. Interpregnancy weight gain and childhood obesity: analysis of a UK population-based cohort. Int J Obes (Lond). 2022;46(1):211-9.

[5]. Heslehurst N, Rankin J, Wilkinson JR, et al. A nationally representative study of maternal obesity in England, UK: trends in incidence and demographic inequalities in 619 323 births, 1989-2007. Int J Obes (Lond). 2010;34(3):420-8.

[6]. Driscoll AK, Gregory ECW. Increases in prepregnancy obesity: United States, 2016–2019. NCHS Data Brief. 2020 Nov:(392):1-8

[7]. Prodan NC, Schmidt M, Hoopmann M, et al. Obesity in prenatal medicine: a game changer? Arch Gynecol Obstet. 2024;309(3):961-74.

[8]. Godfrey KM, Reynolds RM, Prescott SL, et al. Influence of maternal obesity on the long-term health of offspring. Lancet Diabetes Endocrinol. 2017;5(1):53-64.

[9]. Langley-Evans SC. Early life programming of health and disease: the long-term consequences of obesity in pregnancy. J Hum Nutr Diet. 2022;35(5):816-32.

[10]. Derraik JG, Ayyavoo A, Hofman PL, et al. Increasing maternal prepregnancy body mass index is associated with reduced insulin sensitivity and increased blood pressure in their children. Clin Endocrinol (Oxf). 2015;83(3):352-6.

[11]. Rosenquist NA, Richards M, Ferber JR, et al. Maternal obesity and childhood asthma risk: exploring mediating pathways. Paediatr Perinat Epidemiol. 2024;38(4):302-12.

[12]. Eriksson JG, Sandboge S, Salonen MK, et al. Long-term consequences of maternal overweight in pregnancy on offspring later health: findings from the Helsinki birth cohort study. Ann Med. 2014;46(6):434-8.

[13]. Gutvirtz G, Wainstock T, Landau D, et al. Maternal obesity and offspring long-term infectious morbidity. J Clin Med. 2019;8(9):1466.

[14]. Makowski L, Chaib M, Rathmell JC. Immunometabolism: from basic mechanisms to translation. Immunol Rev. 2020;295(1):5-14.

[15]. Pearce EJ, Pearce EL. Immunometabolism in 2017: driving immunity: all roads lead to metabolism. Nat Rev Immunol. 2018;18(2):81-2.

[16]. Odegaard JI, Chawla A. The immune system as a sensor of the metabolic state. Immunity. 2013;38(4):644-54.

[17]. O’Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553-65.

[18]. Martin SS, Aday AW, Allen NB, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 Heart disease and stroke statistics: a report of US and Global Data From The American Heart Association. Circulation. 2025;151(8):e41-e660.

[19]. Oh DY, Morinaga H, Talukdar S, et al. Increased macrophage migration into adipose tissue in obese mice. Diabetes. 2012;61(2):346-54.

[20]. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45.

[21]. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.

[22]. Winer S, Chan Y, Paltser G, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921-9.

[23]. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930-9.

[24]. Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15(8):914-20.

[25]. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28(7):1304-10.

[26]. Anderson EK, Gutierrez DA, Kennedy A, et al. Weight cycling increases T-cell accumulation in adipose tissue and impairs systemic glucose tolerance. Diabetes. 2013;62(9):3180-8.

[27]. Zou J, Lai B, Zheng M, et al. CD4+ T cells memorize obesity and promote weight regain. Cell Mol Immunol. 2018;15(6):630-9.

[28]. Winer DA, Luck H, Tsai S, et al. The intestinal immune system in obesity and insulin resistance. Cell Metab. 2016;23(3):413-26.

[29]. Mayoral Monibas R, Johnson AM, Osborn O, et al. Distinct hepatic macrophage populations in lean and obese mice. Front Endocrinol. 2016;7:152.

[30]. Schmitz J, Evers N, Awazawa M, et al. Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss. Mol Metab. 2016;5(5):328-39.

[31]. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177-85.

[32]. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.

[33]. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409-15.

[34]. Nicholas LM, Nagao M, Kusinski LC, et al. Exposure to maternal obesity programs sex differences in pancreatic islets of the offspring in mice. Diabetologia. 2020;63(2):324-37.

[35]. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175-84.

[36]. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-808.

[37]. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-91.

[38]. Thrum S, Sommer M, Raulien N, et al. Macrophages in obesity are characterised by increased IL-1β response to calcium-sensing receptor signals. Int J Obes (Lond). 2022;46(10):1883-91.

[39]. Bing C. Is interleukin-1β a culprit in macrophage-adipocyte crosstalk in obesity? Adipocyte. 2015;4(2):149-52.

[40]. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8(9):673-5.

[41]. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100(12):7265-70.

[42]. Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda). 2016;31(4):283-93.

[43]. Cani PD, Delzenne NM, Amar J, et al. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris). 2008;56(5):305-9.

[44]. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-81.

[45]. Khan SA, Ali A, Khan SA, et al. Unraveling the complex relationship triad between lipids, obesity, and inflammation. Mediators Inflamm. 2014;2014:502749.

[46]. Rocha DM, Bressan J, Hermsdorff HH. The role of dietary fatty acid intake in inflammatory gene expression: a critical review. Sao Paulo Med J. 2017;135(2):157-68.

[47]. Lee JY, Zhao L, Youn HS, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits toll-like receptor 2 dimerized with toll-like receptor 6 or 1. J Biol Chem. 2004;279(17):16971-9.

[48]. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007;282(48):35279-92.

[49]. Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56(12):2910-8.

[50]. Fischer-Posovszky P, Wang QA, Asterholm IW, et al. Targeted deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. Endocrinology. 2011;152(8):3074-81.

[51]. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347-55.

[52]. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008;100(2):227-35.

[53]. Ye J, Gao Z, Yin J, et al. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab. 2007;293(4):E1118-28.

[54]. Lee YS, Kim JW, Osborne O, et al. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell. 2014;157(6):1339-52.

[55]. Khan T, Muise ES, Iyengar P, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol. 2009;29(6):1575-91.

[56]. Williams AS, Kang L, Wasserman DH. The extracellular matrix and insulin resistance. Trends Endocrinol Metab. 2015;26(7):357-66.

[57]. Lee YS, Li P, Huh JY, et al. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011;60(10):2474-83.

[58]. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34.

[59]. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006;116(7):1813-22.

[60]. Walås A, Simatou E, Andersson Franko M, et al. Maternal overweight and obesity and risk of perinatal Ischemic stroke: a nationwide cohort study. Neurology. 2025;104(6):e213333.

[61]. Denizli M, Capitano ML, Kua KL. Maternal obesity and the impact of associated early-life inflammation on long-term health of offspring. Front Cell Infect Microbiol. 2022;12:940937.

[62]. Murphy CC, Cirillo PM, Krigbaum NY, et al. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. Gut. 2022;71(7):1332-9.

[63]. Moeckli B, Delaune V, Gilbert B, et al. Maternal obesity increases the risk of hepatocellular carcinoma through the transmission of an altered gut microbiome. JHEP Rep. 2024;6(5):101056.

[64]. Liu J, Kharazmi E, Liang Q, et al. Maternal weight during pregnancy and risk of childhood acute lymphoblastic leukemia in offspring. Leukemia. 2025;39(3):590-8.

[65]. Yogev Y, Catalano PM. Pregnancy and obesity. Obstet Gynecol Clin North Am. 2009;36(2):285-300, viii.

[66]. Rogers LK, Velten M. Maternal inflammation, growth retardation, and preterm birth: insights into adult cardiovascular disease. Life Sci. 2011;89(13-14):417-21.

[67]. Lucas A. Programming not metabolic imprinting. Am J Clin Nutr. 2000;71(2):602.

[68]. Reynolds RM, Allan KM, Raja EA, et al. Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years. BMJ. 2013;347:f4539.

[69]. Catalano PM, Presley L, Minium J, et al. Fetuses of obese mothers develop insulin resistance in utero. Diabetes Care. 2009;32(6):1076-80.

[70]. Barker DJ. The origins of the developmental origins theory. J Intern Med. 2007;261(5):412-7.

[71]. Griffith OW, Chavan AR, Protopapas S, et al. Embryo implantation evolved from an ancestral inflammatory attachment reaction. Proc Natl Acad Sci U S A. 2017;114(32):E6566-75.

[72]. McGlade EA, Mao J, Stephens KK, et al. Progesterone signaling in oviductal epithelial cells modulates the immune response to support preimplantation embryonic development. Sci Adv. 2025;11(16):eadt6113.

[73]. Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518(7540):547-51.

[74]. Perdiguero EG, Klapproth K, Schulz C, et al. The origin of tissue-resident macrophages: when an erythro-myeloid progenitor is an erythro-myeloid progenitor. Immunity. 2015;43(6):1023-4.

[75]. Frank L, Postrach D, Langhinrichs M, et al. Holistic genetic barcoding reveals a lineage tree of tissue macrophage development. bioRxiv. Preprint posted online November 30, 2024. doi: 10.1101/2024.11.29.625985.

[76]. He S, Luo C-L, Luo T, et al. Systemic immune activity occurs during human immune system maturation. Cell. 2025;188:7291-308.e23.

[77]. Mass E, Nimmerjahn F, Kierdorf K, et al. Tissue-specific macrophages: how they develop and choreograph tissue biology. Nat Rev Immunol. 2023;23(9):563-79.

[78]. Wang Z, Wu Z, Wang H, et al. An immune cell atlas reveals the dynamics of human macrophage specification during prenatal development. Cell. 2023;186(20):4454-71.e19.

[79]. Schneider Gasser EM, Schaer R, Mueller FS, et al. Prenatal immune activation in mice induces long-term alterations in brain mitochondrial function. Transl Psychiatry. 2024;14(1):289.

[80]. Rees A, Jenkins BJ, Angelini R, et al. Immunometabolic adaptation in monocytes underpins functional changes during pregnancy. iScience. 2024;27(5):109779.

[81]. Feyaerts D, Urbschat C, Gaudillière B, et al. Establishment of tissue-resident immune populations in the fetus. Semin Immunopathol. 2022;44(6):747-66.

[82]. Bellissimo CJ, Beristain AG, Sloboda DM. Impacts of maternal excess adiposity on the uterine immune environment: contributions to placental dysfunction and adverse pregnancy outcomes. Reproduction. 2025;170(2):e240464.

[83]. Musillo C, Ajmone-Cat MA, De Simone R, et al. Maternal stressors disrupt mouse placental proteome and fetal brain development in a sex-specific fashion through inflammation and oxidative stress. Mol Psychiatry. 2025;30(11):5072-83.

[84]. Ramsay JE, Ferrell WR, Crawford L, et al. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab. 2002;87(9):4231-7.

[85]. Aye IL, Lager S, Ramirez VI, et al. Increasing maternal body mass index is associated with systemic inflammation in the mother and the activation of distinct placental inflammatory pathways. Biol Reprod. 2014;90(6):129.

[86]. Hayes LN, An K, Carloni E, et al. Prenatal immune stress blunts microglia reactivity, impairing neurocircuitry. Nature. 2022;610(7931):327-34.

[87]. Agrawal R, Lathia T. Obesity during pregnancy: contemporary evidence and clinical implications. Curr Opin Endocrinol Diabetes Obes. 2025;32(6):286-95.

[88]. Gaur P, Power ML, Schulkin J, et al. Associations of preconception body weight, body mass index, and hypertension with preeclampsia. J Womens Health (Larchmt). 2025;34(11):1374-80.

[89]. Chu SY, Callaghan WM, Kim SY, et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070-6.

[90]. Santos S, Voerman E, Amiano P, et al. Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian cohorts. BJOG. 2019;126(8):984-95.

[91]. Jancsura MK, Helsabeck NP, Anderson CM, et al. Identifying the timing and type of inflammatory markers for potential prediction of preeclampsia in women with obesity. Hypertens Pregnancy. 2025;44(1):2492084.

[92]. Wilson RM, Marshall NE, Jeske DR, et al. Maternal obesity alters immune cell frequencies and responses in umbilical cord blood samples. Pediatr Allergy Immunol. 2015;26(4):344-51.

[93]. Bucher M, Montaniel KRC, Myatt L, et al. Dyslipidemia, insulin resistance, and impairment of placental metabolism in the offspring of obese mothers. J Dev Orig Health Dis. 2021;12(5):738-47.

[94]. Layden AJ, Bertolet M, Parks WT, et al. Prepregnancy obesity and risk of placental inflammation at term: a selection bias analysis. Ann Epidemiol. 2023;86:25-33.e7.

[95]. Monaco-Brown M, Lawrence DA. Obesity and maternal-placental-fetal immunology and health. Front Pediatr. 2022;10:859885.

[96]. Myatt L, Maloyan A. Obesity and placental function. Semin Reprod Med. 2016;34(1):42-9.

[97]. Sferruzzi-Perri AN, Lopez-Tello J, Salazar-Petres E. Placental adaptations supporting fetal growth during normal and adverse gestational environments. Exp Physiol. 2023;108(3):371-97.

[98]. Sureshchandra S, Marshall NE, Wilson RM, et al. Inflammatory determinants of pregravid obesity in placenta and peripheral blood. Front Physiol. 2018;9:1089.

[99]. Christensen AP, Bert S, Nadkarni S. Immune mechanisms of vascular disease in preeclampsia. Arterioscler Thromb Vasc Biol. 2025;45(10):1715-23.

[100]. Xie J, He L, Qin S. Integrated bioinformatics analysis identifies neutrophils and villous cytotrophoblasts infiltration characterized by BLC6 upregulation as associated with the co-occurrence of gestational diabetes mellitus and pre-eclampsia. Hypertens Pregnancy. 2025;44(1):2475814.

[101]. Levy O. Innate immunity of the human newborn: distinct cytokine responses to LPS and other Toll-like receptor agonists. J Endotoxin Res. 2005;11(2):113-6.

[102]. Ibrahim MH, Moustafa AN, Saedii AAF, et al. Cord blood erythropoietin and cord blood nucleated red blood cells for prediction of adverse neonatal outcome associated with maternal obesity in term pregnancy: prospective cohort study. J Matern Fetal Neonatal Med. 2017;30(18):2237-42.

[103]. Gonzalez-Espinosa LO, Montiel-Cervantes LA, Guerra-Márquez A, et al. Maternal obesity associated with increase in natural killer T cells and CD8+ regulatory T cells in cord blood units. Transfusion. 2016;56(5):1075-81.

[104]. Yan X, Huang Y, Wang H, et al. Maternal obesity induces sustained inflammation in both fetal and offspring large intestine of sheep. Inflamm Bowel Dis. 2011;17(7):1513-22.

[105]. Zhu MJ, Du M, Nathanielsz PW, et al. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. Placenta. 2010;31(5):387-91.

[106]. Sureshchandra S, Doratt BM, Mendza N, et al. Maternal obesity blunts antimicrobial responses in fetal monocytes. Elife. 2023;12:e81320.

[107]. Azher S, Pinheiro JMB, Philbin B, et al. The impact of maternal obesity on NICU and newborn nursery costs. Front Pediatr. 2022;10:863165.

[108]. Althaus T, Chasekwa B, Robertson RC, et al. Associations between maternal obesity and infectious morbidity in Zimbabwean infants. Eur J Clin Nutr. 2022;76(2):328-33.

[109]. Huang H, Balzer NR, Seep L, et al. Kupffer cell programming by maternal obesity triggers fatty liver disease. Nature. 2025;644(8077):790-8.

[110]. Wang Z, Lipshutz A, Martínez de la Torre C, et al. Early life high fructose impairs microglial phagocytosis and neurodevelopment. Nature. 2025;644(8077):759-68.

[111]. Ceasrine AM, Devlin BA, Bolton JL, et al. Maternal diet disrupts the placenta-brain axis in a sex-specific manner. Nat Metab. 2022;4(12):1732-45.

[112]. Alharithi YJ, Phillips EA, Wilson TD, et al. Metabolomic and transcriptomic remodeling of bone marrow myeloid cells in response to maternal obesity. Am J Physiol Endocrinol Metab. 2025;328(2):E254-71.

[113]. Basso PJ, Gauthier T, Palomares F, et al. Editorial: Immunometabolism: bridging the gap between immunology and nutrition. Front Nutr. 2024;11:1436894.

[114]. Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin Sci (Lond). 2021;135(6):731-52.

[115]. Boyle CN, Le Foll C. Amylin and leptin interaction: role during pregnancy, lactation and neonatal development. Neuroscience. 2020;447:136-47.

[116]. Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A. 1996;93(25):14564-8.

[117]. Aye IL, Powell TL, Jansson T. Review: Adiponectin--the missing link between maternal adiposity, placental transport and fetal growth? Placenta. 2013;34(Suppl):S40-5.

[118]. Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem. 2010;285(9):6153-60.

[119]. Varin EM, Mulvihill EE, Beaudry JL, et al. Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition. Cell Metab. 2019;29(2):320-34.e5.

[120]. Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1-21.

[121]. Han CK, Lee WF, Hsu CJ, et al. DPP4 reduces proinflammatory cytokine production in human rheumatoid arthritis synovial fibroblasts. J Cell Physiol. 2021;236(12):8060-9.

[122]. Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:386.

[123]. Sun C, Xiao Y, Li J, et al. Nonenzymatic function of DPP4 in diabetes-associated mitochondrial dysfunction and cognitive impairment. Alzheimers Dement. 2022;18(5):966-87.

[124]. Zilleßen P, Celner J, Kretschmann A, et al. Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes. Sci Rep. 2016;6:23074.

[125]. Muir KC, Harris DD, Stone C, et al. Linagliptin exerts a sex-specific effect on cardiac function, collateralization, and metabolism in a swine model of cardiometabolic disease. J Thorac Cardiovasc Surg. 2025;170(6):1659-71.e6.

[126]. Iwabuchi A, Kamoda T, Saito M, et al. Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2013;26(11-12):1093-7.

[127]. Sanz B, Larrinaga G, Fernandez-Atucha A, et al. Obesity parameters, physical activity, and physical fitness are correlated with serum dipeptidyl peptidase IV activity in a healthy population. Heliyon. 2018;4(5):e00627.

[128]. Williams KH, Vieira De Ribeiro AJ, Prakoso E, et al. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: a dual cohort cross-sectional study. J Diabetes. 2015;7(6):809-19.

[129]. Lee JY, Jang BK, Song MK, et al. Association between serum dipeptidyl peptidase-4 concentration and obesity-related factors in health screen examinees (J Obes Metab Syndr 2017;26:188-96). J Obes Metab Syndr. 2018;27(1):73-4.

[130]. Sarkar J, Nargis T, Tantia O, et al. Increased plasma dipeptidyl peptidase-4 (DPP4) activity is an obesity-independent parameter for glycemic deregulation in type 2 diabetes patients. Front Endocrinol (Lausanne). 2019;10:505.

[131]. Ilias I, Thomopoulos C, Michalopoulou H, et al. Antidiabetic drugs and blood pressure changes. Pharmacol Res. 2020;161:105108.

[132]. Kocak A, Aydin E, Gündüz MK, et al. Exploring the nephroprotective effects of combined finerenone and exenatide therapy in diabetic nephropathy. Int Immunopharmacol. 2025;167:115661.

[133]. Koh G. Association between serum dipeptidyl peptidase-4 concentration and obesity-related factors in health screen examinees (J Obes Metab Syndr 2017;26:188-96). J Obes Metab Syndr. 2018;27(1):71-2.

[134]. Lipscombe LL. In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin. Ann Intern Med. 2019;171(4):JC16.

[135]. Ferjan S, Janez A, Jensterle M. Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: a pilot randomized study. Metab Syndr Relat Disord. 2017;15(10):515-20.

[136]. Lind M, Matsson PO, Linder R, et al. Clinical effectiveness of liraglutide vs sitagliptin on glycemic control and body weight in patients with type 2 diabetes: a retrospective assessment in Sweden. Diabetes Ther. 2016;7(2):321-33.

[137]. Hussain M, Atif MA, Tunio AG, et al. Effect of sitagliptin on glycemic control, body weight, blood pressure and serum lipid profile in type 2 diabetic hyperlipidemic patients. J Ayub Med Coll Abbottabad. 2016;28(2):369-72.

[138]. Yanai H, Adachi H, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res. 2012;4(4):251-8.

[139]. Seck TL, Engel SS, Williams-Herman DE, et al. Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res Clin Pract. 2011;93(1):e15-7.

[140]. Waters SB, Topp BG, Siler SQ, et al. Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J Diabetes Sci Technol. 2009;3(1):68-82.

[141]. Yoshikawa K, Tsuchiya A, Kido T, et al. Long-term safety and efficacy of sitagliptin for type 2 diabetes mellitus in Japan: results of a multicentre, open-label, observational post-marketing surveillance study. Adv Ther. 2020;37(5):2442-59.

[142]. Derosa G, Tritto I, Romano D, et al. Effects of sitagliptin on lipid profile in patients with type 2 diabetes mellitus after 7 years of therapy. J Clin Pharmacol. 2019;59(10):1391-9.

[143]. Shi C, Zhang R, Bai R, et al. Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. Clinics (Sao Paulo). 2019;74:e736.

[144]. Takai M, Ishikawa M, Maeda H, et al. Efficacy and safety of adding sitagliptin in type 2 diabetes patients on insulin: age-stratified comparison at one year in the ASSIST-K Study. J Clin Med Res. 2019;11(5):311-20.

[145]. Raji A, Long J, Lam RLH, et al. Efficacy and safety of sitagliptin in hispanic/latino patients with type 2 diabetes: a pooled analysis from ten randomized, placebo-controlled phase 3 clinical trials. Diabetes Ther. 2018;9(4):1581-9.

[146]. Tang Y, Huang X, Liu J, et al. The effects of a sitagliptin formulary restriction program on diabetes medication use. Am Health Drug Benefits. 2017;10(9):456-62.

[147]. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760.

[148]. Marques C, Mega C, Goncalves A, et al. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm. 2014;2014:538737.

[149]. Tremblay AJ, Lamarche B, Deacon CF, et al. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014;63(9):1141-8.

[150]. Best C, Struthers H, Laciny E, et al. Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance. J Clin Endocrinol Metab. 2015;100(7):2621-9.

[151]. Kelany ME, Hakami TM, Omar AH, et al. Combination of sitagliptin and insulin against type 2 diabetes mellitus with neuropathy in rats: neuroprotection and role of oxidative and inflammation stress. Pharmacology. 2016;98(5-6):242-50.

[152]. Esposito G, Cappetta D, Russo R, et al. Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction. Br J Pharmacol. 2017;174(22):4070-86.

[153]. Goncalves A, Almeida L, Silva AP, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation. Biomed Pharmacother. 2018;102:833-8.

[154]. Prakash S, Rai U, Kosuru R, et al. Amelioration of diet-induced metabolic syndrome and fatty liver with sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice. Biochimie. 2020;168:198-209.

[155]. Montaniel KRC, Bucher M, Phillips EA, et al. Dipeptidyl peptidase IV inhibition delays developmental programming of obesity and metabolic disease in male offspring of obese mothers. J Dev Orig Health Dis. 2022;13(6):727-40.

[156]. Nishida S, Matsumura T, Senokuchi T, et al. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increas

引用本文

Alharithi, Yem J.; Smith, Gladys; Maloyan, Alina. Developmental origins of immunometabolic health [J]. Immunometabolism. 2026; 8; (1). - .

文献评论

相关学者

相关机构